Reviewing Mesa Laboratories (NASDAQ:MLAB) & ImmunoPrecise Antibodies (OTCMKTS:IPATF)

Mesa Laboratories (NASDAQ:MLAB) and ImmunoPrecise Antibodies (OTCMKTS:IPATF) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability.

Profitability

This table compares Mesa Laboratories and ImmunoPrecise Antibodies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mesa Laboratories	1.92%	22.72%	9.82%
ImmunoPrecise Antibodies	N/A	N/A	N/A

Insider & Institutional Ownership

90.6% of Mesa Laboratories shares are owned by institutional investors. 2.8% of Mesa Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Mesa Laboratories and ImmunoPrecise Antibodies”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesa Laboratories	$249.13 million	2.38	$6.71 million	$0.84	126.24
ImmunoPrecise Antibodies	N/A	N/A	N/A	N/A	N/A

Mesa Laboratories has higher revenue and earnings than ImmunoPrecise Antibodies.

Analyst Ratings

This is a breakdown of recent ratings for Mesa Laboratories and ImmunoPrecise Antibodies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesa Laboratories	0	3	0	0	2.00
ImmunoPrecise Antibodies	0	0	0	0	0.00

Mesa Laboratories presently has a consensus price target of $110.00, suggesting a potential upside of 3.73%. Given Mesa Laboratories’ stronger consensus rating and higher possible upside, analysts clearly believe Mesa Laboratories is more favorable than ImmunoPrecise Antibodies.

Summary

Mesa Laboratories beats ImmunoPrecise Antibodies on 8 of the 8 factors compared between the two stocks.

About Mesa Laboratories

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment’s products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd. engages in the provision of human therapeutic antibody discovery and development services. It offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. Its services include B cell sorting, screening and sequencing; custom, immune and naive phage display production and screening; bi-specific, tri-specific, VHH, and VNAR antibody manufacturing; antibody engineering; and antibody optimization and humanization. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Victoria, Canada.